269 related articles for article (PubMed ID: 31711124)
1. REToma: a cancer subtype with a shared driver oncogene.
Kohno T; Tabata J; Nakaoku T
Carcinogenesis; 2020 Apr; 41(2):123-129. PubMed ID: 31711124
[TBL] [Abstract][Full Text] [Related]
2. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
3. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
4. Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.
Saleh K; Felefly T; Khalife N; Kourie HR
Pharmacogenomics; 2021 Apr; 22(5):247-250. PubMed ID: 33754802
[No Abstract] [Full Text] [Related]
5. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
6. Development of RET kinase inhibitors for targeted cancer therapy.
Mologni L
Curr Med Chem; 2011; 18(2):162-75. PubMed ID: 21110809
[TBL] [Abstract][Full Text] [Related]
7. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
8. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
9. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
10. [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].
Zheng Y; Jiang W; Chen D; Li Y; Dai L; Huang L; Wang M
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):591-597. PubMed ID: 34120433
[TBL] [Abstract][Full Text] [Related]
11. Hallmarks of RET and Co-occuring Genomic Alterations in
Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
[TBL] [Abstract][Full Text] [Related]
12. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
Saleh K; Khalife N; Felefly T
Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417
[No Abstract] [Full Text] [Related]
13. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
15. Selpercatinib.
Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
[No Abstract] [Full Text] [Related]
16. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
Bruce JY; Bible KC; Chintakuntlawar AV
Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
[No Abstract] [Full Text] [Related]
17. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
19. RET fusion gene: translation to personalized lung cancer therapy.
Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
[TBL] [Abstract][Full Text] [Related]
20. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]